Compare MCBS & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | EVO |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.1M | 895.8M |
| IPO Year | 2019 | N/A |
| Metric | MCBS | EVO |
|---|---|---|
| Price | $28.23 | $2.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.00 | $7.00 |
| AVG Volume (30 Days) | 92.4K | ★ 108.8K |
| Earning Date | 04-17-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 4.76 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.78 | N/A |
| Revenue Next Year | $4.83 | $7.13 |
| P/E Ratio | $10.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.24 | $2.31 |
| 52 Week High | $31.00 | $4.80 |
| Indicator | MCBS | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 34.47 |
| Support Level | $26.87 | $2.31 |
| Resistance Level | $29.08 | $3.78 |
| Average True Range (ATR) | 0.70 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.61 | 25.54 |
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.